Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Dec 29, 2004 4:15pm
157 Views
Post# 8366583

RE: easy money:11/12 january coming news

RE: easy money:11/12 january coming news Hi Guys, I wouldn't put too much stead into the Jan 11th announcement. I honestly didnt get the impression that the follow-on news was particularly relevant ? I imagine it will be more pomp, ceremony and ribbon cutting than anything else given the various government agencies' involvment. Its the imminent CE approval, full Phase One 1402 results and ultimately the launch of the PRDT MacoPharma filters that we really have to look forward to. Those things independently are huge for us. Any other frac plant or recurring revenue business or live animal testing is just gravy in the scope of the other stuff IMHO. While I appreciate and understand the scepticism of the "optimism" on the board. Its exactly the disappointment and long cycle that many of us long timers have been thru that's fundamentally behind the discount between the markets valuation of this company and the underlying fundamentals. These same issues are the same things that have confounded and upset analysts. There has simply been too much stock issued with too few results for far too long . Having said all that, I am a self professed world class sceptic. I have looked at this thing every which way, met with management and IR and I am absolutely convinced that this thing is coming into the sweet spot that we have all been waiting for. There's simply too many good applications of the core technology to go too far wrong. I think management has done an excellent job of platform diversification without giving away much of the upside potential. In the next 6 months we are going to close the valuation gap considerably.
Bullboard Posts